caa a22 4500 469074051 CHVBK 20180323132930.0 cr unu---uuuuu 170328e19920301xx s 000 0 eng 10.1007/BF01741855 doi (NATIONALLICENCE)springer-10.1007/BF01741855 Recruitment of T lymphocytes and induction of tumor necrosis factor in thyroid cancer by a local immunotherapy [Elektronische Daten] [Takashi Misaki, Yoshihiro Watanabe, Yasuhiro Iida, Akinari Hidaka, Kanji Kasagi, Hideyuki Fukushima, Junji Konishi] Summary: To elucidate the mechanism of action for intratumoral injection of immunopotentiators, infiltrating mononuclear cells and tumor necrosis factor (TNF) were assayed by immunostaining tissue samples of differentiated thyroid cancer resected with or without presurgical local application of OK-432, a streptococcal preparation. Frozen sections of resected specimens were stained with monoclonal antibodies using either a conventional or a modified immunoperoxidase method. The tumors injected with OK-432 showed increased T lymphocyte infiltration and HLA-DR expression on cancer cells as compared to the non-injected controls. Among these T cells, the CD4+ subset was more numerous than the CD8+ population. In four out of the seven cases constituting the injected group, numerous TNF-positive cells were seen in clusters or lines as well as scattered, while none of the seven cases in the control group was associated with a considerable amount of these cells. In their morphology and distribution pattern, these TNF-positive cells appeared to be of macrophage lineage. Thus local injection of OK-432 in thyroid cancer was shown to recruit T lymphocytes of predominantly the CD4+ subset and to induce in situ production of TNF, a known potent tumoricidal cytokine. The present data warrant further studies in this direction besides wider clinical intratumoral application of the reagent. Springer-Verlag, 1992 T lymphocyte nationallicence Tumor necrosis factor nationallicence Thyroid cancer nationallicence Misaki Takashi Department of Nuclear Medicine, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut Watanabe Yoshihiro Department of Otonasolaryngology, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut Iida Yasuhiro Department of Nuclear Medicine, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut Hidaka Akinari Department of Nuclear Medicine, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut Kasagi Kanji Department of Nuclear Medicine, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut Fukushima Hideyuki Department of Otonasolaryngology, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut Konishi Junji Department of Nuclear Medicine, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut Cancer Immunology, Immunotherapy Springer-Verlag 35/2(1992-03-01), 92-96 0340-7004 35:2<92 1992 35 262 https://doi.org/10.1007/BF01741855 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF01741855 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Misaki Takashi Department of Nuclear Medicine, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut NATIONALLICENCE 700 1- Watanabe Yoshihiro Department of Otonasolaryngology, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut NATIONALLICENCE 700 1- Iida Yasuhiro Department of Nuclear Medicine, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut NATIONALLICENCE 700 1- Hidaka Akinari Department of Nuclear Medicine, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut NATIONALLICENCE 700 1- Kasagi Kanji Department of Nuclear Medicine, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut NATIONALLICENCE 700 1- Fukushima Hideyuki Department of Otonasolaryngology, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut NATIONALLICENCE 700 1- Konishi Junji Department of Nuclear Medicine, Kyoto University School of Medicine, Shogoin, Sakyoku, 606, Kyoto, Japan aut NATIONALLICENCE 773 0- Cancer Immunology, Immunotherapy Springer-Verlag 35/2(1992-03-01), 92-96 0340-7004 35:2<92 1992 35 262 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer